Cosmo Pharmaceuticals N.V. (CMOPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cosmo Pharmaceuticals N.V. (CMOPF) trades at $83.42 with AI Score 49/100 (Grade C). Cosmo Pharmaceuticals N. V. Market cap: $1.43B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CMOPF: CMOPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CMOPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CMOPF: the 1 perspectives are evenly split.
How is this calculated? →Cosmo Pharmaceuticals N.V. (CMOPF) Healthcare & Pipeline Overview
Cosmo Pharmaceuticals N.V. specializes in developing and commercializing innovative gastroenterology and endoscopy products, leveraging advanced technologies like artificial intelligence to enhance patient outcomes in gastrointestinal care.
What Is the Investment Thesis for CMOPF?
Cosmo Pharmaceuticals N.V. presents a compelling investment thesis driven by its innovative product pipeline and strong market positioning in the gastroenterology sector. The company boasts a market cap of $1.43B and a gross margin of 48.5%, which reflects its operational efficiency and the demand for its specialized products. Key growth catalysts include the increasing prevalence of gastrointestinal disorders and the expansion of its product offerings, particularly with the introduction of AI-driven technologies like GI Genius. The company's strategic partnerships, such as those with RedHill Biopharma Ltd. and Acacia Pharma Group plc, further enhance its market reach and potential for revenue growth. However, investors should remain aware of the ongoing challenges in the pharmaceutical industry, including regulatory hurdles and competition from generic drug manufacturers. Overall, Cosmo's focus on innovation and its established market presence provide a robust foundation for future growth.
Based on FMP financials and quantitative analysis
CMOPF Key Highlights
- Market cap of $1.43B, indicating a strong position in the specialty pharmaceutical sector.
- Gross margin of 48.5%, reflecting operational efficiency and product demand.
- Diverse product portfolio addressing various gastrointestinal conditions.
- Strong focus on innovation with AI-driven diagnostic solutions.
- Strategic partnerships enhancing market reach and development capabilities.
Who Are CMOPF's Competitors?
CMOPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RHHBY Roche Holding AG | $51.62 | -2.68% | $332.48B | 61 |
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| ABBV AbbVie Inc. | $255.67 | -2.07% | $451.72B | 78 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CMOPF's Key Strengths?
- Innovative product portfolio with a focus on gastroenterology and endoscopy.
- Strong gross margin of 48.5%, indicating operational efficiency.
- Established partnerships enhancing product distribution and market reach.
- Expertise in developing AI-driven diagnostic solutions.
What Are CMOPF's Weaknesses?
- Negative profit margin of -3.5%, indicating potential financial challenges.
- Dependence on a limited number of key products for revenue.
- Exposure to regulatory risks associated with pharmaceutical approvals.
- Relatively small size compared to larger competitors in the industry.
What Could Drive CMOPF Stock Higher?
- Anticipated product launches in the next 2-3 years from the expanding pipeline.
- Continued adoption of AI technologies in healthcare diagnostics enhancing market position.
- Strategic partnerships with companies like RedHill Biopharma and Acacia Pharma driving revenue growth.
- Potential regulatory approvals for new products in development.
- Increasing prevalence of gastrointestinal disorders fueling demand for innovative treatments.
What Are the Key Risks for CMOPF?
- Negative return on equity (-0.8%) — the business is not currently generating profit on shareholder capital.
- Regulatory hurdles that could delay product approvals.
- Intense competition from larger pharmaceutical companies.
- Financial challenges reflected in the negative profit margin.
- Market volatility affecting investment in research and development.
- Dependence on a limited number of key products for revenue.
What Are the Growth Opportunities for CMOPF?
- Growth opportunity 1: The increasing prevalence of gastrointestinal disorders, such as ulcerative colitis and irritable bowel syndrome, is expected to drive demand for Cosmo's products. The global gastrointestinal therapeutics market is projected to reach $60 billion by 2028, providing a substantial growth avenue for the company as it expands its product offerings and market presence.
- Growth opportunity 2: The integration of artificial intelligence in diagnostic tools, particularly with the GI Genius system, positions Cosmo at the forefront of technological advancements in the healthcare sector. As healthcare providers increasingly adopt AI solutions to enhance diagnostic accuracy, Cosmo's innovative products could capture significant market share in the growing $10 billion AI healthcare market over the next five years.
- Growth opportunity 3: The expansion of Cosmo's product pipeline, including new formulations and treatments for gastrointestinal conditions, presents a strategic growth avenue. The company is actively pursuing research and development initiatives that could yield new products, with potential market launches anticipated within the next 2-3 years, further solidifying its position in the specialty pharmaceutical market.
- Growth opportunity 4: Strategic partnerships and licensing agreements, such as those with RedHill Biopharma and Acacia Pharma, enhance Cosmo's capabilities to penetrate new markets and diversify its product offerings. These collaborations could lead to increased revenue streams and market expansion, particularly in regions with high unmet medical needs.
- Growth opportunity 5: The rising demand for minimally invasive procedures in gastroenterology aligns with Cosmo's offerings, such as Eleview and ByFavo. The market for minimally invasive surgical techniques is projected to grow at a CAGR of 7% through 2027, providing Cosmo with opportunities to capitalize on this trend with its innovative products.
What Opportunities Does CMOPF Have?
- Growing demand for innovative gastrointestinal therapies and diagnostics.
- Expansion of the product pipeline with new formulations and treatments.
- Increased adoption of AI technologies in healthcare diagnostics.
- Potential for market expansion through strategic partnerships.
What Threats Does CMOPF Face?
- Intense competition from established pharmaceutical companies and generic manufacturers.
- Regulatory hurdles that could delay product approvals and market entry.
- Market volatility affecting funding for research and development.
- Potential patent expirations leading to increased competition.
What Are CMOPF's Competitive Advantages?
- Strong focus on innovation and advanced technologies, such as AI in diagnostics.
- Established reputation in the specialty pharmaceutical market.
- Diverse product portfolio addressing a range of gastrointestinal conditions.
- Strategic partnerships enhancing market presence and product offerings.
- Commitment to research and development for continuous product improvement.
What Does CMOPF Do?
Founded in 1997 and headquartered in Dublin, Ireland, Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative products for gastroenterology and endoscopy. The company has established a strong market presence with a diverse portfolio that includes well-known products such as Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, which are used for managing ulcerative colitis. In addition to these oral formulations, Cosmo has made significant strides in the field of diagnostic and therapeutic solutions with products like GI Genius, an artificial intelligence system designed to detect colorectal polyps, and Methylene Blue MMX, a diagnostic drug that enhances the detection of precancerous and cancerous lesions during colonoscopy. Cosmo's offerings also include Eleview, an injectable composition for gastrointestinal endoscopic procedures, and Aemcolo/Relafalk, which addresses various gastrointestinal conditions. The company is committed to advancing treatment options in gastroenterology, with ongoing research and development efforts aimed at expanding its product pipeline. Cosmo Pharmaceuticals operates globally, leveraging partnerships and licensing agreements to enhance its reach and impact in the healthcare sector, positioning itself competitively among peers in the specialty pharmaceutical market.
What Products and Services Does CMOPF Offer?
- Develop and commercialize specialty pharmaceutical products for gastroenterology and endoscopy.
- Offer innovative treatments for conditions like ulcerative colitis and irritable bowel syndrome.
- Utilize artificial intelligence in diagnostic tools to enhance colorectal polyp detection.
- Provide injectable compositions for gastrointestinal endoscopic procedures.
- Market a range of products addressing various gastrointestinal disorders.
- Engage in strategic partnerships to expand product offerings and market reach.
How Does CMOPF Make Money?
- Generate revenue through the sale of specialty pharmaceutical products.
- Leverage partnerships and licensing agreements to enhance product distribution.
- Invest in research and development to innovate and expand the product pipeline.
- Focus on high-demand therapeutic areas within gastroenterology and endoscopy.
- Utilize advanced technologies to differentiate products in the market.
What Industry Does CMOPF Operate In?
The drug manufacturing industry, particularly in the specialty and generic sectors, is experiencing significant growth driven by increasing healthcare needs and advancements in technology. The global market for gastroenterology products is expanding, with a growing emphasis on innovative treatments and diagnostics. Cosmo Pharmaceuticals N.V. is well-positioned within this landscape, leveraging its expertise to address the rising prevalence of gastrointestinal disorders. The competitive landscape includes various players, but Cosmo differentiates itself through its focus on specialized products and cutting-edge technologies, such as AI in diagnostics, which are becoming increasingly important in improving patient outcomes.
Who Are CMOPF's Key Customers?
- Healthcare providers and hospitals specializing in gastroenterology.
- Pharmacies and distributors of pharmaceutical products.
- Patients suffering from gastrointestinal disorders.
- Research institutions involved in gastrointestinal health studies.
- Healthcare systems looking for innovative diagnostic solutions.
ROE -1%Key Financial Metrics
Return on equity for Cosmo Pharmaceuticals N.V. stands at -0.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.3%, the inverse of the P/E and a quick read on earnings relative to price.
Cosmo Pharmaceuticals N.V. (CMOPF) Valuation Context
Valued at $1.43B, CMOPF is classified as a small-cap stock. Relative to its peer group, CMOPF's quantitative score of 49/100 is below the peer average of 81/100.
Company Profile
Cosmo Pharmaceuticals N.V. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Giovanni Di Napoli. CMOPF has traded publicly since 2017.
F-Score 8/9Financial Health
Cosmo Pharmaceuticals N.V.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.45 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Cosmo Pharmaceuticals N.V. revenue of about $103.4M for fiscal 2026, with EPS near $0.10. The estimate reflects 6 contributing analysts.
CMOPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Cosmo seems to be gaining traction in the market's eye lately. Positive chatter in the community suggests a growing belief in their long-term strategy and potential for growth.
- Recent insider activity, although not always a guarantee, hints at confidence from within the company. Someone's betting on their own horse.
- There's a growing sense that Cosmo's core business is becoming more resilient. People are talking about their ability to weather market volatility.
- The overall sentiment seems to be shifting from cautious to optimistic. The community is starting to see potential catalysts that could drive the stock higher.
Bear Case
- Despite the optimism, some in the community are worried about increasing competition in their sector. The market is a battlefield, and the fight is getting tougher.
- There's concern that Cosmo might be overvalued compared to its peers. The price might be running ahead of the fundamentals.
- Some investors are skeptical about the company's ability to execute its long-term plans. The road to success is paved with good intentions, but execution is key.
- The market perception, while improving, still has pockets of doubt. Some believe the positive sentiment is more hype than substance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CMOPF Latest News
No recent news available for CMOPF.
CMOPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CMOPF.
Price Targets
Wall Street price target analysis for CMOPF.
CMOPF MoonshotScore
What does this score mean?
The MoonshotScore rates CMOPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Giovanni Di Napoli
CEO
Giovanni Di Napoli has extensive experience in the pharmaceutical industry, having held various leadership roles since joining Cosmo Pharmaceuticals N.V. He has a strong background in business development and strategic planning, with a focus on driving innovation in healthcare. Di Napoli holds an advanced degree in pharmaceutical sciences and has been instrumental in expanding Cosmo's product portfolio and market presence.
Track Record: Under Giovanni Di Napoli's leadership, Cosmo Pharmaceuticals has successfully launched several key products and established strategic partnerships that have enhanced its market position. His focus on innovation and operational efficiency has contributed to the company's growth trajectory and commitment to improving patient outcomes.
CMOPF OTC Market Information
Cosmo Pharmaceuticals N.V. trades on the OTC Other tier, which includes companies that do not meet the listing requirements for major exchanges like NYSE or NASDAQ. This tier typically has less stringent reporting standards and may have lower liquidity compared to listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity compared to stocks on major exchanges, leading to higher volatility.
- Limited financial disclosures may hinder comprehensive analysis.
- Potential for wider bid-ask spreads affecting trading costs.
- Regulatory risks associated with OTC trading.
- Review financial statements and disclosures for accuracy.
- Assess the company's product pipeline and market potential.
- Evaluate the competitive landscape and market positioning.
- Investigate any pending regulatory approvals or challenges.
- Monitor news and updates related to partnerships and collaborations.
- Established history since 1997 in the pharmaceutical industry.
- Partnerships with recognized companies such as RedHill Biopharma.
- Innovative product offerings that address significant healthcare needs.
Cosmo Pharmaceuticals N.V. Healthcare Stock: Key Questions Answered
What does Cosmo Pharmaceuticals N.V. do?
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing innovative products for gastroenterology and endoscopy. Its product portfolio includes treatments for various gastrointestinal conditions, diagnostic tools utilizing artificial intelligence, and injectable compositions for endoscopic procedures, positioning the company as a leader in its field.
How does Cosmo Pharmaceuticals N.V. manage patent expiration risks?
Cosmo Pharmaceuticals N.V. actively engages in lifecycle management strategies to mitigate patent expiration risks, including developing new formulations and expanding its product pipeline. The company also focuses on innovation to maintain a competitive edge against generic competitors, ensuring continued revenue streams.
What is Cosmo Pharmaceuticals N.V.'s drug pipeline status?
Cosmo Pharmaceuticals N.V. has a robust drug pipeline with several products in various stages of development. The company is focused on expanding its offerings in gastroenterology, with anticipated product launches expected within the next 2-3 years, which could significantly enhance its market presence and revenue potential.
What are the key factors to evaluate for CMOPF?
Cosmo Pharmaceuticals N.V. (CMOPF) holds an AI score of 49/100 (low). Not financial advice.
How frequently does CMOPF data refresh on this page?
CMOPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CMOPF's recent stock price performance?
Cosmo Pharmaceuticals N.V. (CMOPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio with a focus on gastroenterology and endoscopy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CMOPF overvalued or undervalued right now?
Valuing Cosmo Pharmaceuticals N.V. (CMOPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CMOPF?
Before investing in Cosmo Pharmaceuticals N.V. (CMOPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available information and may be subject to change.